Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Infliximab.

E Valle1, M Gross, S J Bickston

  • 1The Digestive Health Center, University of Virginia Health System, Charlottesville 22908, USA.

Expert Opinion on Pharmacotherapy
|October 5, 2001
PubMed
Summary
This summary is machine-generated.

Infliximab, a monoclonal antibody, effectively treats moderate to severe Crohn's disease and rheumatoid arthritis. Despite high costs, over 150,000 patients have benefited from this significant therapeutic advancement since 1998.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Time-activity budget in horses and ponies: A systematic review and meta-analysis on feeding dynamics and management implications.

Journal of equine veterinary science·2025
Same author

Clinical nutrition counselling service in the veterinary hospital: retrospective analysis of equine patients and nutritional considerations.

Journal of animal physiology and animal nutrition·2017
Same author

Vagus nerve stimulation therapy for treatment-resistant epilepsy: a 15-year experience at a single institution.

Clinical neurology and neurosurgery·2015
Same author

RUMINANT NUTRITION SYMPOSIUM: Use of genomics and transcriptomics to identify strategies to lower ruminal methanogenesis.

Journal of animal science·2015
Same author

Effects of competition on acute phase proteins and lymphocyte subpopulations - oxidative stress markers in eventing horses.

Journal of animal physiology and animal nutrition·2015
Same author

Effect of adjuvant trastuzumab treatment in conventional clinical setting: an observational retrospective multicenter Italian study.

Breast cancer research and treatment·2013
Same journal

Pharmacotherapeutic interventions for pediatric ulcerative colitis.

Expert opinion on pharmacotherapy·2026
Same journal

The rise and fall of TRPV1-targeted analgesia in osteoarthritis: a critical appraisal.

Expert opinion on pharmacotherapy·2026
Same journal

Dopamine transporter and beyond: evolving targets and combination strategies in stimulant use disorder.

Expert opinion on pharmacotherapy·2026
Same journal

GnRH antagonists for the treatment of fibroids and adenomyosis, current evidence and future perspectives.

Expert opinion on pharmacotherapy·2026
Same journal

Pharmacotherapeutic strategies for the management of congenital adrenal hyperplasia.

Expert opinion on pharmacotherapy·2026
Same journal

Current advances in pharmacotherapeutic strategies for the treatment of complicated intra-abdominal infections.

Expert opinion on pharmacotherapy·2026
See all related articles

Area of Science:

  • Immunology
  • Gastroenterology
  • Rheumatology

Background:

  • Infliximab (Remicade) is a monoclonal antibody targeting TNF.
  • It was introduced in 1998 for moderate to severe Crohn's disease.
  • Significant therapeutic advancement in inflammatory disease treatment.

Purpose of the Study:

  • To evaluate the efficacy of Infliximab in treating Crohn's disease.
  • To highlight its expanded indications in fistulising CD and rheumatoid arthritis.
  • To provide an overview of its clinical adoption and impact.

Main Methods:

  • Intravenous administration of Infliximab.
  • Clinical trials demonstrating efficacy in Crohn's disease and rheumatoid arthritis.
  • Post-marketing surveillance of patient outcomes.

Related Experiment Videos

Main Results:

  • Proven efficacy in moderate to severe Crohn's disease.
  • Demonstrated effectiveness in fistulising Crohn's disease and rheumatoid arthritis.
  • Widespread patient adoption exceeding 150,000 infusions.

Conclusions:

  • Infliximab represents a major therapeutic option for inflammatory conditions.
  • Its efficacy is established across multiple autoimmune indications.
  • Despite high cost, it has seen significant clinical utilization.